基于PSAD、活检路径与靶向穿刺针数对PI-RADS 3病变风险适配性省略系统穿刺的多中心队列研究
该多中心回顾性队列纳入902例PI-RADS 3病变行融合活检的男性,评估仅靶向穿刺(TBx)相比总体活检(OBx)的绝对遗漏成本。TBx检出csPCa 181例(20%),OBx检出240例(27%),TBx遗漏59例,绝对遗漏成本6.5%(95%CI 5.0-8.4),超过预设5%探索性界值。当csPCa定义为ISUP≥3时遗漏成本降至2.8%(25/902;95%CI 1.8-4.1)。
要点
- PI-RADS 3病变仅行TBx的绝对遗漏成本为6.5%,超过5%探索性界值。
- 经会阴穿刺且PSAD<0.10 ng/ml/cm3者遗漏成本最低(0.8%,1/126)。
- 每增加1针靶向穿刺与TBx失败风险降低独立相关(aOR 0.69)。
核心结论
- 当csPCa定义为ISUP≥2时,PI-RADS 3病变仅行TBx不应作为OBx的普遍替代方案。
- 更严格显著性阈值下遗漏成本降低及低PSAD经会阴穿刺者的低遗漏成本支持前瞻性评估风险适配性活检降级。
- 这些探索性发现不足以支持常规省略系统穿刺。
研究设计与样本
- 回顾性多中心队列研究,纳入902例活检前mpMRI仅PI-RADS 3病变且接受首次软件辅助mpMRI-超声融合活检的男性。
- 6家学术及高容量中心,2016年1月至2023年3月。
- 所有患者同次会话经会阴或经直肠路径行TBx和SBx。
主要发现
- TBx检出csPCa 181/902(20%),OBx检出240/902(27%)。
- TBx遗漏59例,绝对遗漏成本6.5%(95%CI 5.0-8.4)。
- csPCa定义为ISUP≥3时,遗漏成本2.8%(25/902;95%CI 1.8-4.1)。
- 经会阴穿刺且PSAD<0.10 ng/ml/cm3者遗漏成本最低:0.8%(1/126;95%CI 0.02-4.3)。
- 每增加1针靶向穿刺与TBx失败风险降低独立相关(aOR 0.69,95%CI 0.54-0.86)。
关键数值与推荐
- csPCa定义为主要分析采用ISUP grade group≥2,敏感性分析采用ISUP grade group≥3。
- 探索性5%界值用于情境化评估TBx单独策略的表现。
- TBx失败相关因素采用多变量Firth惩罚logistic回归评估。
临床怎么用
- PI-RADS 3病变不应常规省略系统穿刺。
- 对低PSAD(<0.10 ng/ml/cm3)且经会阴穿刺者可考虑前瞻性评估活检降级策略。
- 增加靶向穿刺针数可能降低TBx失败风险,但需结合其他因素综合决策。
局限性
- 回顾性设计。
- 中心间mpMRI判读和活检实践存在异质性。
- 活检路径非随机选择。
- 参考标准为同次会话联合活检而非全器官病理。
- 缺乏逐针空间定位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate Imaging Reporting and Data System (PI-RADS) category 3 lesions represent an intermediate-risk group for which the additional diagnostic value of systematic biopsy (SBx) after multiparametric magnetic resonance imaging (mpMRI)-targeted biopsy (TBx) remains uncertain. OBJECTIVE: To quantify the absolute omission cost of a TBx-only strategy compared with overall biopsy (OBx; TBx plus SBx) and to assess whether this cost varies according to prostate-specific antigen density (PSAD), biopsy route, and targeted sampling intensity. DESIGN, SETTING, AND PARTICIPANTS: This retrospective multicentre cohort study included 902 men with exclusively PI-RADS 3 lesions on prebiopsy mpMRI who underwent index software-assisted mpMRI-ultrasound fusion biopsy at six academic and high-volume centres between January 2016 and March 2023. INTERVENTION: All patients underwent same-session TBx and SBx via either the transperineal (TP) or transrectal (TR) route. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was the absolute cohort-level proportion of clinically significant prostate cancer (csPCa), defined as International Society of Urological Pathology (ISUP) grade group ≥2, detected by OBx but missed by TBx. Paired detection rates were compared using the McNemar test, and the omission cost was estimated with exact confidence intervals (CIs). An exploratory 5% margin was used to contextualise the performance of TBx alone. Factors associated with TBx failure were evaluated using multivariable Firth penalised logistic regression. A sensitivity analysis defined csPCa as ISUP grade group ≥3. RESULTS AND LIMITATIONS: TBx detected csPCa in 181 of 902 men (20%), whereas OBx detected csPCa in 240 (27%). TBx alone missed 59 cases, corresponding to an absolute omission cost of 6.5% (95% CI 5.0-8.4), which exceeded the prespecified exploratory 5% benchmark. When csPCa was defined as ISUP grade group ≥3, the omission cost decreased to 2.8% (25/902; 95% CI 1.8-4.1). The lowest omission cost was observed among men undergoing TP biopsy with PSAD <0.10 ng/ml/cm3 (0.8%, 1/126; 95% CI 0.02-4.3). Each additional targeted core was independently associated with lower odds of TBx failure (adjusted odds ratio 0.69, 95% CI 0.54-0.86). Limitations include the retrospective design, centre-level heterogeneity in mpMRI interpretation and biopsy practices, nonrandom biopsy-route selection, the use of same-session combined biopsy rather than whole-mount pathology as the reference standard, and the absence of core-by-core spatial mapping. CONCLUSIONS: TBx alone should not be considered a universal substitute for OBx in men with PI-RADS 3 lesions when csPCa is defined as ISUP grade group ≥2. The lower omission cost observed when a stricter threshold for significant disease was applied, and in selected men with low PSAD undergoing TP biopsy, supports prospective evaluation of risk-adapted biopsy deintensification. However, these exploratory findings do not justify the routine omission of SBx.
引用
- Buhas BA, Mjaess G, Diamand R, et al. Risk-adapted Omission of Systematic Cores in PI-RADS 3 Lesions Based on Prostate-specific Antigen Density, Biopsy Route, and Targeted Core Number: A Multicentre Cohort Study. Eur Urol Oncol. 2026. PMID: 42532809. doi:10.1016/j.euo.2026.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。